Germany's Merck has announced its biggest investment in
pharmaceuticals in its 338-year-old history, as its top-selling
oncology drug Erbitux (cetuximab) has driven the company to
allocate €190m for the construction of its first...
Scientists in the US have found out how the enzyme helps initiate
the process that leads to colorectal cancer. Their discovery of a
new molecular mechanism by which an enzyme promotes cancer spread
may provide a new target at which...
The first pharmacogenetic laboratory test for use as a companion
diagnostic to a specific drug therapy has been approved by the FDA.
The test represents a new area of pharmacogenomics in which
molecular diagnostic and drug pairings...
According to a latest study, which revealed the presence of a
unique genetic biomarker, the quality of life for patients
undergoing treatment for colorectal cancer may be significantly
improved, potentially minimising the unwanted...
Xantos Biomedicine, NascaCell and PSF biotech have announced the
formation of a collaboration, which is set to identify and develop
new drugs for the inhibition of tumour angiogenesis, a process by
which the growth of blood cells...
FDA's approval of Sanofi-Aventis' Eloxatin (oxaliplatin) is
unlikely to increase the drug's patient base, but the new
formulation should consolidate Sanofi-Aventis' position as the
largest pharmaceutical firm in...
Switzerland's Roche made a piece of medical history on Friday after
receiving the first approval for a drug designed to treat cancer
blocking the growth of blood vessels required to feed a growing
Lonza has signed two new agreements for the supply of monoclonal
antibody-based drugs that provide an early fillip for its contract
manufacturing business, which was adversely affected by
overcapacity in 2003.
Germany's KGaA has announced plans to sell off its laboratory
distribution business VWR International and operate as a smaller,
higher-margin business focused on pharmaceuticals, chemicals and
2003 was the second best year of all time for the biotechnology
industry, and 2004 looks set to be even better. This is the verdict
of James Burrill, head of US merchant bank Burrill & Co, who
describes the industry as "rising...